Table of Contents
ISRN Allergy
Volume 2013, Article ID 561831, 6 pages
http://dx.doi.org/10.1155/2013/561831
Research Article

Sustained Elevation of Systemic Oxidative Stress and Inflammation in Exacerbation and Remission of Asthma

1Division of Respiratory Medicine, Departments of Medicine, The University of Hong Kong, Hong Kong
2Pharmacology & Pharmacy, The University of Hong Kong, Hong Kong
3Research Centre for Heart, Brain, Hormone and Healthy Aging, The University of Hong Kong, Hong Kong
4Room L8-40, Laboratory Block, LKS Faculty of Medicine Building, The University of Hong Kong, 21 Sassoon Road, Hong Kong
5Alice Ho Miu Ling Nethersole Hospital, Tai Po, Hong Kong

Received 4 June 2013; Accepted 1 August 2013

Academic Editors: S. Burastero, B. F. Gibbs, A. Lorentz, and T. Oga

Copyright © 2013 Judith C. W. Mak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. J. Barnes, “Pathophysiology of asthma,” British Journal of Clinical Pharmacology, vol. 42, no. 1, pp. 3–10, 1996. View at Google Scholar · View at Scopus
  2. L. G. Wood, P. G. Gibson, and M. L. Garg, “Biomarkers of lipid peroxidation, airway inflammation and asthma,” European Respiratory Journal, vol. 21, no. 1, pp. 177–186, 2003. View at Google Scholar · View at Scopus
  3. P. A. B. Wark and P. G. Gibson, “Asthma exacerbations · 3: pathogenesis,” Thorax, vol. 61, no. 10, pp. 909–915, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. J. D. Morrow and L. J. Roberts, “The isoprostanes: their role as an index of oxidant stress status in human pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 12, pp. S25–S30, 2002. View at Google Scholar · View at Scopus
  5. P. Montuschi, M. Corradi, G. Ciabattoni, J. Nightingale, S. A. Kharitonov, and P. J. Barnes, “Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients,” American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 1, pp. 216–220, 1999. View at Google Scholar · View at Scopus
  6. L. G. Wood, D. A. Fitzgerald, P. C. Gibson, D. M. Cooper, and M. L. Garg, “Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma,” Lipids, vol. 35, no. 9, pp. 967–974, 2000. View at Google Scholar · View at Scopus
  7. L. C. Wood, M. L. Garg, J. L. Simpson et al., “Induced sputum 8-isoprostane concentrations in inflammatory airway diseases,” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 5, pp. 426–430, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. K. R. Shanmugasundaram, S. S. Kumar, and S. Rajajee, “Excessive free radical generation in the blood of children suffering from asthma,” Clinica Chimica Acta, vol. 305, no. 1-2, pp. 107–114, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Baraldi, S. Carraro, R. Alinovi et al., “Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations,” Thorax, vol. 58, no. 6, pp. 505–509, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Suzuki, S. Matsukura, H. Takeuchi et al., “Increase in reactive oxygen metabolite level in acute exacerbations of asthma,” International Archives of Allergy and Immunology, vol. 146, supplement 1, pp. 67–72, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. B. Pepys and G. M. Hirschfield, “C-reactive protein: a critical update,” Journal of Clinical Investigation, vol. 111, no. 12, pp. 1805–1812, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Sävykoski, T. Harju, M. Paldanius et al., “Chlamydia pneumoniae infection and inflammation in adults with asthma,” Respiration, vol. 71, no. 2, pp. 120–125, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. I. S. Ólafsdottir, T. Gislason, B. Thjodleifsson et al., “C reactive protein levels are increased in non-allergic but not allergic asthma: a multicentre epidemiological study,” Thorax, vol. 60, no. 6, pp. 451–454, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Takemura, H. Matsumoto, A. Niimi et al., “High sensitivity C-reactive protein in asthma,” European Respiratory Journal, vol. 27, no. 5, pp. 908–912, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Kasayama, M. Tanemura, M. Koga, K. Fujita, H. Yamamoto, and A. Miyatake, “Asthma is an independent risk for elevation of plasma C-reactive protein levels,” Clinica Chimica Acta, vol. 399, no. 1-2, pp. 79–82, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. Z. Zietkowski, M. M. Tomasiak-Lozowska, R. Skiepko, B. Mroczko, M. Szmitkowski, and A. Bodzenta-Lukaszyk, “High-sensitivity C-reactive protein in the exhaled breath condensate and serum in stable and unstable asthma,” Respiratory Medicine, vol. 103, no. 3, pp. 379–385, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. H. Allam, A. F. Said, A. A. El Samie Omran, D. M. Abd El-Reheim, and A. H. Kasem, “High sensitivity C-reactive protein: its correlation with sputum cell counts in bronchial asthma,” Respiratory Medicine, vol. 103, no. 12, pp. 1878–1884, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Fujita, S. Ueki, W. Ito et al., “C-reactive protein levels in the serum of asthmatic patients,” Annals of Allergy, Asthma and Immunology, vol. 99, no. 1, pp. 48–53, 2007. View at Google Scholar · View at Scopus
  19. H. Ohbayashi and K. Shimokata, “Matrix metalloproteinase-9 and airway remodeling in asthma,” Current Drug Targets, vol. 4, no. 2, pp. 177–181, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Mautino, N. Oliver, P. Chanez, J. Bousquet, and F. Capony, “Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics,” American Journal of Respiratory Cell and Molecular Biology, vol. 17, no. 5, pp. 583–591, 1997. View at Google Scholar · View at Scopus
  21. A. M. Vignola, L. Riccobono, A. Mirabella et al., “Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis,” American Journal of Respiratory and Critical Care Medicine, vol. 158, no. 6, pp. 1945–1950, 1998. View at Google Scholar · View at Scopus
  22. D. Cataldo, C. Munaut, A. Noël et al., “MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease,” International Archives of Allergy and Immunology, vol. 123, no. 3, pp. 259–267, 2000. View at Google Scholar · View at Scopus
  23. M. Bossé, J. Chakir, M. Rouabhia, L.-P. Boulet, M. Audette, and M. Laviolette, “Serum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase- 1 ratio correlates with steroid responsiveness in moderate to severe asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 2, pp. 596–602, 1999. View at Google Scholar · View at Scopus
  24. I. Ohno, H. Ohtani, Y. Nitta et al., “Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation,” American Journal of Respiratory Cell and Molecular Biology, vol. 16, no. 3, pp. 212–219, 1997. View at Google Scholar · View at Scopus
  25. W. Mattos, S. Lim, R. Russell, A. Jatakanon, K. F. Chung, and P. J. Barnes, “Matrix metalloproteinase-9 expression in asthma: effect of asthma severity, allergen challenge, and inhaled corticosteroids,” Chest, vol. 122, no. 5, pp. 1543–1552, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Belleguic, M. Corbel, N. Germain et al., “Increased release of matrix metalloproteinase-9 in the plasma of acute severe asthmatic patients,” Clinical and Experimental Allergy, vol. 32, no. 2, pp. 217–223, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. Global Initiative for Asthma (GINA), “Global strategy for asthma management and prevention, 2011,” March 2013, http://www.ginasthma.org/.
  28. “Standardization of spirometry: 1994 update,” American Journal of Respiratory and Critical Care Medicine, vol. 152, no. 3, pp. 1107–1136, 1995. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Soferman, M. Glatstein, Y. Sivan, and Y. Weisman, “HsCRP levels: measurement of airway inflammation in asthmatic children,” Pediatrics International, vol. 50, no. 1, pp. 12–16, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Oshita, T. Koga, T. Kamimura, K. Matsuo, T. Rikimaru, and H. Aizawa, “Increased circulating 92 kDa matrix metalloproteinase (MMP-9) activity in exacerbations of asthma,” Thorax, vol. 58, no. 9, pp. 757–760, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Hoshino, M. Takahashi, Y. Takai, and J. Sim, “Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma,” Journal of Allergy and Clinical Immunology, vol. 104, no. 2 I, pp. 356–363, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. C. Lee, H. B. Lee, Y. K. Rhee, and C. H. Song, “The involvement of matrix metalloproteinase-9 in airway inflammation of patients with acute asthma,” Clinical and Experimental Allergy, vol. 31, no. 10, pp. 1623–1630, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. A. C. Staff, T. Ranheim, T. Henriksen, and B. Halvorsen, “8-iso-prostaglandin F2α reduces trophoblast invasion and matrix metalloproteinase activity,” Hypertension, vol. 35, no. 6, pp. 1307–1313, 2000. View at Publisher · View at Google Scholar · View at Scopus